Close Menu

NEW YORK (360Dx) – Bühlmann Laboratories said Thursday that it has received US Food and Drug Administration clearance for its fCal ELISA assay, which uses the measurement of calprotectin protein in human stool to diagnose inflammatory bowel disease, more specifically Crohn’s disease and ulcerative colitis. The assay can also be used in conjunction with other laboratory and clinical findings to differentiate IBD from irritable bowel syndrome, the firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.